Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
gynäkologie + geburtshilfe
Erschienen in: gynäkologie + geburtshilfe 2/2017

08.04.2017 | Präeklampsie | Fortbildung

Die Ära der non-invasiven Pränataldiagnostik (NIPT)

Moderne Konzepte des Ersttrimester-Screenings

verfasst von: Philipp Wagner, Markus Hoopmann, Prof. Dr. med. Karl Oliver Kagan

Erschienen in: gynäkologie + geburtshilfe | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die heutige Schwangerschaftsvorsorge ist darauf angelegt, Komplikationen zu erkennen und Patientinnen frühzeitig zu behandeln. Dieses Betreuungskonzept fußt auf der Annahme, dass die Häufigkeit der meisten Komplikationen mit ansteigendem Schwangerschaftsalter zunehmen, weswegen auch die Frequenz der Untersuchungen mit höherem Gestationsalter steigt. Durch die inzwischen zahlreichen Möglichkeiten des Ersttrimester-Screenings wird die Sicht auf die „klassische“ Schwangerschaftsvorsorge immer häufiger infrage gestellt. Bereits am Ende des ersten Trimenons lässt sich das Risiko für eine Vielzahl von Problemen einschätzen, die erst im späteren Verlauf der Schwangerschaft manifest werden, und teilweise eine effektive Prävention betreiben.
Literatur
1.
Snijders R, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10.14 weeks of gestation. Lancet. 1998 Aug;352(9125):343–6.
2.
Cuckle H, Maymon R. Development of prenatal screening.A historical overview. Seminars in Perinatology. Elsevier; 2016 Jan 22;40(1):12–22.
3.
Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2008;31(6):618–24.CrossRefPubMed
4.
Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2008 Sep;32(4):488–92.CrossRefPubMed
5.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free -hCG and pregnancy-associated plasma protein-A. Human Reproduction. 2008 Jun 20;23(9):1968–75.CrossRefPubMed
6.
Maiz N, Wright D, Ferreira AFA, Syngelaki A, Nicolaides KH. A Mixture Model of Ductus Venosus Pulsatility Index in Screening for Aneuploidies at 11.13 Weeks’ Gestation. Fetal Diagn Ther. 2012;31(4):221–9.CrossRefPubMed
7.
Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11 + 0 to 13 + 6 weeks of gestation. Ultrasound Obstet Gynecol. 2009 Jan;33(1):18–22.CrossRefPubMed
8.
Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 2009 Mar;33(3):259–64.CrossRefPubMed
9.
Cuckle HS, Wald NJ, Thompson SG. Estimating a woman”s risk of having a pregnancy associated with Down”s syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol. 1987 May;94(5):387–402.CrossRefPubMed
10.
Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol. 1999 Mar;13(3):167–70.CrossRefPubMed
11.
Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH. Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21. Ultrasound Obstet Gynecol. 2009 Jun;33(6):657–64.CrossRefPubMed
12.
Abele H, Wagner N, Hoopmann M, Grischke EM, Wallwiener D, Kagan KO. Effect of deviation from the mid-sagittal plane on the measurement of fetal nuchal translucency. Ultrasound Obstet Gynecol. 2010 Feb 24;35(5):525–9.CrossRefPubMed
13.
Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH. Relation between increased fetal nuchal translucency thickness and chromosomal defects. Obstet Gynecol. 2006 Jan;107(1):6–10.CrossRefPubMed
14.
Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol. 2008;31(4):376–83.CrossRefPubMed
15.
Baer RJ, Norton ME, Shaw GM, Flessel MC, Goldman S, Currier RJ, et al. Risk of selected structural abnormalities in infants after increased nuchal translucency measurement. Am J Obstet Gynecol. Elsevier; 2014 Dec;211(6):675–e1.19.
16.
Souka AP, Kaisenberg Von CS, Hyett JA, Sonek JD, Nicolaides KH. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol. Elsevier; 2005 Apr;192(4):1005–21.CrossRef
17.
Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol. 2008;31(5):493–502.CrossRefPubMed
18.
Merz E, Thode C, Eiben B, Faber R, Hackeloer BJ, Huesgen G, et al. Individualized correction for maternal weight in calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall in Med. 2011 Feb;32(1):33–9.CrossRef
19.
Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagn Ther. Karger Publishers; 2014;35(2):118–26.CrossRef
20.
Abele H, Wagner P, Sonek J, Hoopmann M, Brucker S, Artunc-Ulkumen B, et al. First trimester ultrasound screening for Down syndrome based on maternal age, fetal nuchal translucency and different combinations of the additional markers nasal bone, tricuspid and ductus venosus flow. Prenat Diagn. 2015 Dec;35(12):1182–6.CrossRefPubMed
21.
Kagan KO, Hoopmann M, Abele H, Alkier R, Luthgens K. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2012 Nov 5;40(5):530–5.CrossRefPubMed
22.
Wagner P, Sonek J, Hoopmann M, Abele H, Kagan KO. First-trimester screening for trisomies 18 and 13, triploidy and Turner syndrome by detailed early anomaly scan. Ultrasound in Obstetrics & Gynecology. John Wiley & Sons, Ltd; 2016 Oct;48(4):446–51.
23.
Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound in Obstetrics & Gynecology. John Wiley & Sons, Ltd; 2015 Mar;45(3):249–66.
24.
Grati FR, Kagan KO. No test result rate of cfDNA analysis and its influence on test performance metrics. Ultrasound in Obstetrics & Gynecology. John Wiley & Sons, Ltd; 2016 Oct 1.
25.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol. 2013 Jul;42(1):41–50.CrossRefPubMed
26.
Kagan K, Schmid M, Hoopmann M, Wagner P, Abele H. Screening Performance and Costs of Different Strategies in Prenatal Screening for Trisomy 21. Geburtsh Frauenheilk. 2015 Apr 14;75(03):244–50.CrossRefPubMedPubMedCentral
27.
Eiben B, Glaubitz R, Kagan KO. Non-invasive prenatal diagnostics. medgen. 2014 Dec 2;26(4):382–90.CrossRef
28.
Everett TR, Chitty LS. Cell-free fetal DNA: the new tool in fetal medicine. Ultrasound in Obstetrics & Gynecology. 2015 May;45(5):499–507.CrossRef
29.
Wapner RJ, Babiarz JE, Levy B, Stosic M, Zimmermann B, Sigurjonsson S, et al. Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am J Obstet Gynecol. Elsevier; 2015 Mar;212(3):332–e1.9.
30.
Rempen A, Chaoui R, Hausler M, Kagan KO, Kozlowski P, Kaisenberg von C, et al. Quality Requirements for Ultrasound Examination in Early Pregnancy (DEGUM Level I) between 4+0 and 13+6 Weeks of Gestation. Ultraschall Med. 2016 Dec;37(6):579–83.CrossRefPubMed
31.
Rossi AC, Prefumo F. Accuracy of ultrasonography at 11-14 weeks of gestation for detection of fetal structural anomalies: a systematic review. - PubMed - NCBI. Obstet Gynecol. 2013 Dec;122(6):1160–7.CrossRefPubMed
32.
Pereira S, Ganapathy R, Syngelaki A, Maiz N, Nicolaides KH. Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Obstet Gynecol. 2011 Jun;117(6):1384–91.CrossRefPubMed
33.
Salomon LJ, Alfirevic Z, Bilardo CM, Chalouhi GE, Ghi T, Kagan KO, et al. ISUOG practice guidelines: performance of first-trimester fetal ultrasound scan. Ultrasound Obstet Gynecol. 2013 Jan;41(1):102–13.CrossRefPubMed
34.
Kaisenberg von C, Chaoui R, Hausler M, Kagan K, Kozlowski P, Merz E, et al. Quality Requirements for the early Fetal Ultrasound Assessment at 11.13+6 Weeks of Gestation (DEGUM Levels II and III). Ultraschall in Med. 2016 Jun 8;37(03):297–302.CrossRef
35.
Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Chitty LS, Lau TK, editors. Prenat Diagn. 2011 Jan 5;31(1):90–102.CrossRef
36.
Bilardo CM, Muller MA, Pajkrt E, Clur SA, van Zalen MM, Bijlsma EK. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol. 2007 Jul;30(1):11–8.CrossRefPubMed
37.
Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH. Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol. John Wiley & Sons, Ltd; 2005 Aug;26(2):154–7.
38.
Chaoui R, Nicolaides KH. From nuchal translucency to intracranial translucency: towards the early detection of spina bifida. Ultrasound Obstet Gynecol. 2010 Feb;35(2):133–8.CrossRefPubMed
39.
Chen FCK, Gerhardt J, Entezami M, Chaoui R, Henrich W. Detection of Spina Bifida by First Trimester Screening - Results of the Prospective Multicenter Berlin IT-Study. Ultraschall Med. 2015 Apr 14.
40.
Engels AC, Joyeux L, Brantner C et al. Sonographic detection of central nervous system defects in the first trimester of pregnancy. Prenat Diagn. 2016 Mar; 36(3): 266–73.CrossRefPubMed
41.
Khalil A, Coates A, Papageorghiou A, Bhide A, Thilaganathan B. Biparietal diameter at 11-13 weeks' gestation in fetuses with open spina bifida. Ultrasound in Obstetrics & Gynecology. John Wiley & Sons, Ltd; 2013 Oct;42(4):409–15.
42.
Volpe P, Contro E, Fanelli T, Muto B, Pilu G, Gentile M. Appearance of fetal posterior fossa at 11.14 weeks in fetuses with Dandy.Walker malformation or chromosomal anomalies. Ultrasound in Obstetrics & Gynecology. John Wiley & Sons, Ltd; 2016 Jun 1;47(6):720–5.
43.
Sepulveda W, Wong AE, Martinez-Ten P, Perez-Pedregosa J. Retronasal triangle: a sonographic landmark for the screening of cleft palate in the first trimester. Ultrasound in Obstetrics & Gynecology. 2010 Jan;35(1):7–13.CrossRef
44.
Chaoui R, Orosz G, Heling KS, Sarut Lopez A, Nicolaides KH. Maxillary gap at 11-13 weeks' gestation: marker of cleft lip and palate. Ultrasound in Obstetrics & Gynecology. 2015 Dec;46(6):665–9.
45.
Hoopmann M, Sonek J, Esser T, Bilardo CM, Wagner P, Abele H, et al. Frontal space distance in facial clefts and retrognathia at 1-13 weeks’ gestation. Ultrasound Obstet Gynecol. 2016 Aug 2;48(2):171–6.CrossRefPubMed
46.
Sebire NJ, Snijders RJ, Hughes K, Sepulveda W, Nicolaides KH. The hidden mortality of monochorionic twin pregnancies. Br J Obstet Gynaecol. 1997 Oct;104(10):1203–7.CrossRefPubMed
47.
Khalil A, Rodgers M, Baschat A, Bhide A, Gratacos E, Hecher K, et al. ISUOG Practice Guidelines: role of ultrasound in twin pregnancy. Vol. 47, Ultrasound in Obstetrics & Gynecology. 2016. pp. 247–63.CrossRef
48.
Sepulveda W, Sebire NJ, Hughes K, Odibo A, Nicolaides KH. The lambda sign at 10–14 weeks of gestation as a predictor of chorionicity in twin pregnancies. Ultrasound Obstet Gynecol. Blackwell Science Ltd; 1996 Jun;7(6):421–3.
49.
Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, Sotiriadis A, Nicolaides KH. Discordance in nuchal translucency thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol. 2007;29(5):527.32.
50.
Matias A, Montenegro N, Loureiro T, Cunha M, Duarte S, Freitas D, Severo M. Screening for twin-twin transfusion syndrome at 11–14 weeks of pregnancy: the key role of ductus venosus blood flow assessment. Ultrasound Obstet Gynecol. John Wiley & Sons, Ltd; 2010 Feb;35(2):142.8.
51.
Thilaganathan B. Placental syndromes: getting to the heart of the matter. Ghossein-Doha C, Khalil A, Lees C, editors. Ultrasound in Obstetrics & Gynecology. John Wiley & Sons, Ltd; 2017 Jan 1;49(1):7–9.
52.
Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010 Aug;116(2 Pt 1):402–14.CrossRefPubMed
53.
Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2013 Apr 22;41(5):491–9.CrossRefPubMed
54.
O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, et al. Accuracy of competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation. Ultrasound in Obstetrics & Gynecology. 2017 Jan 9.
55.
Wright D, Akolekar R, Syngelaki A, Poon LCY, Nicolaides KH. A Competing Risks Model in Early Screening for Preeclampsia. Fetal Diagn Ther. 2012;32(3):171–8.CrossRefPubMed
56.
Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn. 2014 Jul;34(7):618–27.PubMed
57.
Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, et al. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound in Obstetrics & Gynecology. John Wiley & Sons, Ltd; 2015 Oct;46(4):419–23.CrossRef
58.
Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. Elsevier; 2017 Feb;216(2):110–6.CrossRef
59.
Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001 Nov 24;323(7323):1213–7.CrossRefPubMedPubMedCentral
60.
Poon L, Syngelaki A, Akolekar R, Lai J. Combined screening for preeclampsia and small for gestational age at 11.13 weeks. Fetal Diagn Ther. 2013; 33(1):16–27.CrossRefPubMed
61.
Kagan KO, Sonek J. How to measure cervical length. Ultrasound in Obstetrics & Gynecology. 2015 Mar;45(3):358–62.CrossRef
62.
Greco E, Gupta R, Syngelaki A, Poon LCY, Nicolaides KH. First-Trimester Screening for Spontaneous Preterm Delivery with Maternal Characteristics and Cervical Length. Fetal Diagn Ther. 2012;31(3):154–61.CrossRefPubMed
63.
Retzke JD, Sonek JD, Lehmann J, Yazdi B, Kagan KO. Comparison of three methods of cervical measurement in the first trimester: single-line, two-line, and tracing. Prenat Diagn. 2013 Mar;33(3):262–8.CrossRefPubMed
64.
Syngelaki A, Pastides A, Kotecha R, Wright A, Akolekar R, Nicolaides KH. First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History. Fetal Diagn Ther. 2015;38(1):14–21.CrossRefPubMed
65.
Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn. 2011 Feb;31(2):135–41.CrossRefPubMed
66.
Frick AP, Syngelaki A, Zheng M, Poon LC, Nicolaides KH. Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of pregnancy. Ultrasound in Obstetrics & Gynecology. 2016 Mar;47(3):332–9.CrossRef
67.
Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, et al. Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. N Engl J Med. 2016 Feb 4;374(5):434–43.CrossRefPubMed
68.
Nicolaides KH. A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment. Chitty LS, Lau TK, editors. Prenat Diagn. 2011 Jan 5;31(1):3–6.CrossRefPubMed
69.
Sonek JD, Kagan KO, Nicolaides KH. Inverted Pyramid of Care. Clin Lab Med. 2016 Jun;36(2):305–17.CrossRefPubMed
70.
Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 2009 May;33(5):512–7.CrossRefPubMed
71.
Revello R, Sarno L, Ispas A, Akolekar R, Nicolaides KH. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result. Ultrasound in Obstetrics & Gynecology. John Wiley & Sons, Ltd; 2016 Jun 1;47(6):698–704.CrossRef
72.
Nicolaides KH, Musci TJ, Struble CA, Syngelaki A, Gil MM. Assessment of fetal sex chromosome aneuploidy using directed cell-free DNA analysis. Fetal Diagn Ther. Karger Publishers; 2014;35(1):1–6.CrossRef
Metadaten
Titel
Die Ära der non-invasiven Pränataldiagnostik (NIPT)
Moderne Konzepte des Ersttrimester-Screenings
verfasst von
Philipp Wagner
Markus Hoopmann
Prof. Dr. med. Karl Oliver Kagan
Publikationsdatum
08.04.2017
Verlag
Springer Medizin
Schlagwörter
Präeklampsie
Trisomie 21
Erschienen in
gynäkologie + geburtshilfe / Ausgabe 2/2017
Print ISSN: 1439-3557
Elektronische ISSN: 2196-6435
DOI
https://doi.org/10.1007/s15013-017-1139-6

Weitere Artikel der Ausgabe 2/2017

gynäkologie + geburtshilfe 2/2017 Zur Ausgabe

Industrieforum

Hebammen in Ausbildung profitieren von Training an Geburtssimulator

Medizin aktuell

Wieder mit einer Stimme sprechen

Fortbildung

Menopausale Hormontherapie und Gefäßgesundheit

Industrieforum

HER2-positives Mamma-Ca: Perjeta in der adjuvanten Therapie signifikant überlegen

Medizin aktuell

Möglichkeiten der Reproduktionsmedizin – eine kritische Analyse

Die letzte Seite

Die Mutter Courage der Moderne

Das könnte Sie auch interessieren

03.11.2016 | Schwangerenvorsorge | Kongressbericht | Nachrichten

Schwangerenvorsorge zwischen Fürsorge und Übertreibung

26.05.2016 | Präeklampsie | GenoGyn_Nachrichten

Die neuen Risiken in der Geburtsmedizin

08.12.2015 | Geburtshilfe und Perinatologie | Video-Artikel | Online-Artikel

NIPT: Wie Sie werdende Eltern richtig beraten

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 | Depression antepartal oder postpartal | Nachrichten

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika
weitere anzeigen

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise